Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Setting RCT ‘Health’ Endpoints Suggested To Measure Supplement Efficacy

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplement industry researchers should move away from the medicine model in trials, the scientific director for KGK Synergize says. Researchers should consider new endpoints more appropriate for supplements than for drug ingredients.

You may also be interested in...



NCCAM Strategy Stresses Steps Toward Better Trials For Supplements

The nutritional product industry expects benefits from the National Center for Complementary and Alternative Medicine draft strategic plan's emphasis on funding more preliminary research needed to launch informative clinical trials on supplement ingredients

Coty Continues Licensing Spree With Etro; CEO Nabi Shares Prestige Fragrance Vision

At CAGNY 2024, CEO Sue Nabi discussed Coty’s prestige fragrance strategy, including growing emphasis on ultra-premium offerings and continued focus on fashion-driven licenses, the same day the company announced a long-term fragrance licensing deal with Italian brand Etro.

China Drags On Shiseido, Kao In 2023; Sally Beauty Partners With Black Hair Experience; Beauty News

Shiseido and Kao report China and travel retail were significant headwinds in 2023, though both expect smoother sailing ahead. More beauty news in brief.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel